Case reports
Useful for describing individual events and raising safety questions, but unable to determine causation, average benefit, or who is at risk.
Clinical brief · literature scope through 2026
Evidence Summary
A concise synthesis of what the scientific literature can—and cannot—say about ibogaine, noribogaine, and schizophrenia-spectrum conditions.
Direct evidence
No randomized trials for psychotic disorders
Human literature
Mostly substance-use and safety contexts
Clinical meaning
Research interest is not established care
01 / Scope
What the available literature addresses
Ibogaine is a psychoactive indole alkaloid, and noribogaine is a principal metabolite studied for its pharmacology and duration of action. General background sources describe ibogaine’s psychoactive profile, but that background should not be mistaken for evidence of benefit in schizophrenia.
Published material relevant to ibogaine commonly includes case reports, observational descriptions, safety reports, preclinical work, and human studies in other indications—especially substance-use disorder contexts. Those study types can identify signals, harms, and questions. They do not by themselves establish that an intervention treats a psychotic disorder.
For a broader orientation to the topic and the questions people bring to it, the main clinical brief on ibogaine and schizophrenia sets out the safety-first context. This page narrows the focus to evidence type, relevance, and the limits of inference.
The central finding is not a positive or negative treatment result. It is an evidence gap: direct, controlled clinical evidence for schizophrenia-spectrum conditions is absent.
02 / Study types
Signals from adjacent research are not outcomes for psychosis
Human ibogaine research has often examined experiences or outcomes associated with substance use. Such findings may be relevant to questions about feasibility, exposure, acute effects, monitoring, or follow-up within those populations. They do not answer whether ibogaine improves hallucinations, delusions, disorganization, negative symptoms, relapse risk, functioning, or quality of life in schizophrenia.
Observational work
Can describe associations in selected settings, yet is vulnerable to selection effects, confounding, incomplete follow-up, and variable assessment.
Other-indication trials
May inform research methods or adverse-event surveillance, but their participant populations and outcomes do not transfer automatically to psychosis.
Preclinical studies
Can support mechanistic hypotheses, not clinical conclusions about effectiveness or safety in people with schizophrenia-spectrum conditions.
03 / Translation problem
Why substance-use findings cannot be carried over
Studies in substance-use disorder research frequently use outcomes such as changes in substance use, withdrawal experience, craving, retention, or self-reported change. These are not interchangeable with validated outcomes for schizophrenia. A result in one clinical context cannot establish efficacy or acceptable risk in another without direct investigation.
Who was studied?
Participants in other indications may differ substantially in diagnosis, medications, vulnerability, and care setting.
What changed?
Substance-use outcomes do not measure symptom domains or functional outcomes relevant to psychotic disorders.
What follows?
Direct trials are needed before claims about schizophrenia could be evaluated responsibly.
The distinction matters because schizophrenia is a complex psychiatric condition with varied symptom patterns, courses, and treatment needs. The National Institute of Mental Health overview of schizophrenia describes the condition in terms that underscore why diagnosis-specific outcomes and careful clinical assessment are essential.
04 / Limits and safety relevance
Methodological limits shape the meaning of every claim
Questions it can help frame
Reports outside psychosis may help identify pharmacologic questions, describe protocols used in particular settings, or document adverse events that merit attention in future research design.
Answers it does not provide
It cannot show that ibogaine or noribogaine is effective for schizophrenia, establish a favorable benefit–risk balance for this population, or replace diagnostic assessment and established care.
Important limitations recur across the literature: small samples, uncontrolled designs, self-selection, uncertain product exposure, incomplete medical and psychiatric characterization, nonstandard outcome measures, and limited long-term follow-up. In this setting, reports of subjective change cannot be treated as proof of symptom remission or safety.
Safety questions are also clinically material. The U.S. Food and Drug Administration maintains a public warning on ibogaine treatment safety concerns, including serious medical risks described in its communication. Those concerns do not resolve psychiatric efficacy; they reinforce the need for caution in interpreting claims made outside controlled research.
05 / Questions and answers
What the current evidence gap means in practice
Are there randomized controlled trials supporting ibogaine for schizophrenia?
No randomized controlled trials supporting ibogaine or noribogaine as a treatment for schizophrenia-spectrum disorders were identified in the scope of this brief through 2026. Without direct trials, there is no reliable basis for claims of efficacy, dosing, durability, or an acceptable benefit–risk balance for psychotic disorders.
Do reports from substance-use research demonstrate psychiatric benefit?
No. Outcomes observed in substance-use research are specific to the populations, settings, measures, and study designs used in that work. They cannot be converted into evidence of benefit for psychosis without direct studies using psychiatric outcomes and appropriate safeguards.
What would research need to answer before clinical use could be considered?
Research would need clear eligibility criteria, careful psychiatric and medical screening, transparent accounting of concomitant medication, validated symptom and functioning outcomes, systematic adverse-event monitoring, adequate follow-up, and controlled comparisons. The site’s clinical guidance questions explain why those missing details matter when weighing broad online claims.
Current synthesis
No clinical case for use in psychotic disorders has been established.
The present literature does not provide randomized controlled evidence supporting ibogaine or noribogaine for schizophrenia-spectrum conditions. Findings from other indications may generate research questions, but they do not establish treatment benefit for psychosis. Before clinical use could be considered, the unanswered questions are basic and substantial: who could be studied safely, which outcomes would matter, what harms might occur, how would interactions and follow-up be managed, and how would any result compare with established care?
For background on the project’s evidence-first approach and boundaries, see the resource’s stated purpose and principles. Independent long-form context is also available through the ibogaine documentary project, but documentary material is not a substitute for controlled clinical evidence.